Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. Background: Three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results